<DOC>
	<DOCNO>NCT02399813</DOCNO>
	<brief_summary>This single arm Phase 2 study . Stage 1 2 study monotherapy evaluation ADXS11-001 31 24 subject , respectively persistent/recurrent , loco-regional metastatic SCCA anorectal canal receive least 1 regimen treatment advance disease</brief_summary>
	<brief_title>Phase 2 Study ADXS11-001 Subjects With Carcinoma Anorectal Canal</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<criteria>Must cancer anal canal OR rectal cancer . Must metastatic disease persistent/recurrent locoregional disease Prior Therapy : may receive &lt; 2 regimen disease metastatic setting . At least one line therapy . Be willing able provide write informed consent trial . Be â‰¥18 year age day sign informed consent . Have measurable disease base RECIST 1.1 Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Demonstrate adequate organ function define protocol . Females pregnant breastfeeding must take two method birth control</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>